McNeil Oversight Changes: Johnson & Johnson is replacing two company group chairmen who had been charged with turning around the McNeil Consumer Healthcare unit after a series of recalls, the WSJ reports . Patrick Mutchler, charged with overseeing McNeil last April, is retiring and will be replaced by Roberto Marques. Meantime, the duties of Pericles Stamatiades, chief strategist for J&J’s consumer business since last spring, will be divvied up between other company officials when he departs the company, the WSJ says. Denice Torres will continue to lead day-to-day operations at the McNeil unit. Circumcision Research: With research pointing to circumcision of adult heterosexual males as an effective way to curb the spread of HIV, experimental devices to make the procedure quicker and safer are being tested, the New York Times reports . One, called PrePex, uses a rubber band to cut off blood flow to the foreskin, which can then be painlessly clipped off, the paper says. Hedgehog Success:

The FDA approved Erivedge, a drug to treat advanced basal-cell skin cancer from Roche’s Genentech unit, the WSJ reports . The drug targets the hedgehog pathway, which is thought to play a role in several forms of cancer and is the subject of drug-development efforts by Pfizer, Bristol-Myers Squibb, Novartis and Infinity Pharmaceuticals, the paper says. No Switching: People covered by state high-risk health insurance pools that predated the health-care overhaul may be looking enviously at the newer pre-existing condition insurance plans created by the law because of their often cheaper and more comprehensive coverage, Kaiser Health News’ Insuring Your Health column reports . Those in the older pools can’t just switch to a PCIP because the requirements for participation include being uninsured for six months, KHN reports. The requirement was put in place to keep a lid on PCIP costs. Image: iStockphoto

Here is the original: 
A.M. Vitals: J&J Shakes Up Oversight of McNeil Unit